Skip to main navigation
DURECT
  • ABOUT
    • ABOUT DURECT
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • CORPORATE GOVERNANCE
      • BOARD COMMITTEE CHARTERS
      • CODE OF ETHICS
      • WHISTLEBLOWER POLICY
      • CORPORATE GOVERNANCE GUIDELINES
    • CAREERS
  • MEDICINES
    • POSIMIR® (bupivacaine solution)
  • PIPELINE
    • OVERVIEW
    • LARSUCOSTEROL (DUR-928)
      • OVERVIEW
      • EPIGENETIC REGULATION
      • HOW LARSUCOSTEROL WORKS (VIDEO)
      • ALCOHOL-ASSOCIATED HEPATITIS
      • NONALCOHOLIC STEATOHEPATITIS (NASH)
      • PUBLICATIONS
      • EXPANDED ACCESS POLICY
  • CLINICAL TRIALS
    • AHFIRM
  • TECHNOLOGIES
    • LONG-ACTING INJECTABLES
      • SABER® PLATFORM
      • CLOUD™ PLATFORM
    • ALZET® Osmotic Pumps
  • INVESTORS

    Investor Relations

    • Overview
    • FACTSHEETS
    • Stock Information
    • News Releases
    • Collaborations
    • Earnings Estimate
    • Analyst Coverage
    • Corporate Presentation
    • SEC Filings
    • Event Calendar
    • FAQs
    • E-mail Alerts
    • Information Request
  • NEWS
    • NEWS RELEASES
    • MEDIA KIT

INVESTORS

Investor Relations

  • Overview
  • FACTSHEETS
  • Stock Information
  • News Releases
  • Collaborations
  • Earnings Estimate
  • Analyst Coverage
  • Corporate Presentation
  • SEC Filings
  • Event Calendar
  • FAQs
  • E-mail Alerts
  • Information Request

Factsheets

Show all

  • Corporate Factsheet 486.8 KB
  • Alcohol-Associated Hepatitis (AH) Factsheet 458.2 KB
  • Phase 2 Data Factsheet 95 KB

© 2000-2022 DURECT Corporation

BUSINESS DEVELOPMENT | CAREERS | CONTACT | LEGAL NOTICE | PRIVACY POLICY